203 related articles for article (PubMed ID: 7930943)
1. Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.
Chen PW; Ullrich SE; Ananthaswamy HN
J Leukoc Biol; 1994 Oct; 56(4):469-74. PubMed ID: 7930943
[TBL] [Abstract][Full Text] [Related]
2. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
3. The extracellular domains of MHC class II molecules determine their processing requirements for antigen presentation.
Kjer-Nielsen L; Perera JD; Boyd LF; Margulies DH; McCluskey J
J Immunol; 1990 Apr; 144(8):2915-24. PubMed ID: 1969876
[TBL] [Abstract][Full Text] [Related]
4. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme.
Brooks A; Hartley S; Kjer-Nielsen L; Perera J; Goodnow CC; Basten A; McCluskey J
Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3290-4. PubMed ID: 1707537
[TBL] [Abstract][Full Text] [Related]
5. Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.
Calin-Laurens V; Forquet F; Mottez E; Kanellopoulos J; Godeau F; Kourilsky P; Gerlier D; Rabourdin-Combe C
Eur J Immunol; 1991 Mar; 21(3):761-9. PubMed ID: 2009914
[TBL] [Abstract][Full Text] [Related]
6. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
7. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
[TBL] [Abstract][Full Text] [Related]
8. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
9. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells.
Brooks AG; McCluskey J
J Immunol; 1993 May; 150(9):3690-7. PubMed ID: 8473726
[TBL] [Abstract][Full Text] [Related]
10. Processing of an endogenous protein can generate MHC class II-restricted T cell determinants distinct from those derived from exogenous antigen.
Moreno J; Vignali DA; Nadimi F; Fuchs S; Adorini L; Hämmerling GJ
J Immunol; 1991 Nov; 147(10):3306-13. PubMed ID: 1658143
[TBL] [Abstract][Full Text] [Related]
11. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunother; 1998 May; 21(3):218-24. PubMed ID: 9610914
[TBL] [Abstract][Full Text] [Related]
12. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
13. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
14. Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain.
Nadimi F; Moreno J; Momburg F; Heuser A; Fuchs S; Adorini L; Hämmerling GJ
Eur J Immunol; 1991 May; 21(5):1255-63. PubMed ID: 2037011
[TBL] [Abstract][Full Text] [Related]
15. Membrane Ia expression and antigen-presenting accessory cell function of L cells transfected with class II major histocompatibility complex genes.
Norcross MA; Bentley DM; Margulies DH; Germain RN
J Exp Med; 1984 Nov; 160(5):1316-37. PubMed ID: 6436430
[TBL] [Abstract][Full Text] [Related]
16. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
Kosugi A; Yoshioka T; Suda T; Sano H; Takahama Y; Fujiwara H; Hamaoka T
J Leukoc Biol; 1987 Dec; 42(6):632-41. PubMed ID: 2960766
[TBL] [Abstract][Full Text] [Related]
17. High efficiency of endogenous antigen presentation by MHC class II molecules.
Calin-Laurens V; Forquet F; Lombard-Platet S; Bertolino P; Chrétien I; Trescol-Biémont MC; Gerlier D; Rabourdin-Combe C
Int Immunol; 1992 Oct; 4(10):1113-21. PubMed ID: 1336977
[TBL] [Abstract][Full Text] [Related]
18. Generation of hen egg lysozyme-specific and major histocompatibility complex class I-restricted cytolytic T lymphocytes: recognition of cytosolic and secreted antigen expressed by transfected cells.
Forquet F; Calin V; Trescol-Biemont MC; Kanellopoulos J; Mottez E; Kourilsky P; Rabourdin-Combe C; Gerlier D
Eur J Immunol; 1990 Oct; 20(10):2325-32. PubMed ID: 2242761
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
[TBL] [Abstract][Full Text] [Related]
20. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
